HPV16 seropositivity relatively common prior to diagnosis of anal cancer
the ONA take:
According to a new study published online in the Journal of Clinical Oncology, researchers from the National Cancer Institute in Bethesda, Maryland, have found that human papillomavirus (HPV) type 16 (HPV16) seropositivity is relatively common in people prior to receiving a diagnosis of anal cancer.
Because the European Prospective Investigation Into Cancer and Nutrition Study found that HPV16 E6 seropositivity was present in people more than 10 years prior to being diagnosed with oropharyngeal cancer, researchers sought to investigate the extent to which HPV16 E6 seropositivity was present before the diagnosis of anogenital cancers.
Researchers identified 400 cases of anogenital cancers and 718 matched control in which prediagnostic blood samples were available. Results showed that 29.2% of those who later developed anal cancer had HPV16 E6 seropositivity compared with 0.6% of controls (OR = 75.9).
HPV16 E6 seropositivity was less common in patients who later developed cervical, penilee, vaginal, and vulvar cancers. HPV16 E6 seropositivity was more common in blood samples drawn closer in time to diagnosis.
HPV16 seropositivity is relatively common in people prior to receiving a diagnosis of anal cancer.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Mammograms (Fact Sheet)
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|